glp 1 receptor agonist use and risk of suicide death suicide attempt in users GLP-1 agonists: a nationwide case-time-control study GLP-1 Meds Linked to 265

GoodRx reports that while satisfaction with GLP-1s for weight loss is high, costs and access issues significantly impact patient experiences.

Discover how GLP-1 and GLP-1/GIP therapies (semaglutide and tirzepatide) influence body composition

While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited

It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.

Check with your health insurance or your employer health program to see if it is covered

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials